These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
177 related articles for article (PubMed ID: 37364775)
21. Outcome of Second Allogeneic Hematopoietic Cell Transplantation after Relapse of Myeloid Malignancies following Allogeneic Hematopoietic Cell Transplantation: A Retrospective Cohort on Behalf of the Grupo Español de Trasplante Hematopoyetico. Orti G; Sanz J; Bermudez A; Caballero D; Martinez C; Sierra J; Cabrera Marin JR; Espigado I; Solano C; Ferrà C; García-Noblejas A; Jimenez S; Sampol A; Yañez L; García-Gutiérrez V; Pascual MJ; Jurado M; Moraleda JM; Valcarcel D; Sanz MA; Carreras E; Duarte RF Biol Blood Marrow Transplant; 2016 Mar; 22(3):584-8. PubMed ID: 26631751 [TBL] [Abstract][Full Text] [Related]
22. Antithymocyte globulin in reduced-intensity conditioning regimen allows a high disease-free survival exempt of long-term chronic graft-versus-host disease. Devillier R; Fürst S; El-Cheikh J; Castagna L; Harbi S; Granata A; Crocchiolo R; Oudin C; Mohty B; Bouabdallah R; Chabannon C; Stoppa AM; Charbonnier A; Broussais-Guillaumot F; Calmels B; Lemarie C; Rey J; Vey N; Blaise D Biol Blood Marrow Transplant; 2014 Mar; 20(3):370-4. PubMed ID: 24315846 [TBL] [Abstract][Full Text] [Related]
23. Real-world economic burden of hematopoietic cell transplantation among a large US commercially insured population with hematologic malignancies. Bonafede M; Richhariya A; Cai Q; Josephson NC; McMorrow D; Garfin PM; Perales MA J Med Econ; 2017 Dec; 20(12):1244-1251. PubMed ID: 28782449 [TBL] [Abstract][Full Text] [Related]
24. Clinical Outcomes and Healthcare Resource Utilization for Gastrointestinal Acute Graft-versus-Host Disease after Allogeneic Transplantation for Hematologic Malignancy: A Retrospective US Administrative Claims Database Analysis. Johnson BH; Taylor A; Kim G; Drahos J; Yang J; Akbari M; Shah NN Biol Blood Marrow Transplant; 2019 Apr; 25(4):834-841. PubMed ID: 30625389 [TBL] [Abstract][Full Text] [Related]
25. Significant Risk of Graft-versus-Host Disease with Exposure to Checkpoint Inhibitors before and after Allogeneic Transplantation. Ijaz A; Khan AY; Malik SU; Faridi W; Fraz MA; Usman M; Tariq MJ; Durer S; Durer C; Russ A; Parr NNC; Baig Z; Sagar F; Ali Z; McBride A; Anwer F Biol Blood Marrow Transplant; 2019 Jan; 25(1):94-99. PubMed ID: 30195074 [TBL] [Abstract][Full Text] [Related]
26. Assessment of Individual versus Composite Endpoints of Acute Graft-versus-Host Disease in Determining Long-Term Survival after Allogeneic Transplantation. Magenau J; Braun T; Gatza E; Churay T; Mazzoli A; Chappell G; Brisson J; Runaas L; Anand S; Ghosh M; Riwes M; Pawarode A; Yanik G; Reddy P; Choi SW Biol Blood Marrow Transplant; 2019 Aug; 25(8):1682-1688. PubMed ID: 30710686 [TBL] [Abstract][Full Text] [Related]
27. Post-Transplantation Cyclophosphamide for Graft-versus- Host Disease Prophylaxis in Multiple Myeloma Patients Who Underwent Allogeneic Hematopoietic Cell Transplantation: First Comparison by Donor Type. A Study from the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation. Sahebi F; Eikema DJ; Koster L; Kroger N; Meijer E; van Doesum JA; Rovira M; Koc Y; Angelucci E; Blaise D; Sammassimo S; McDonald A; Arroyo CH; Sanchez JF; Forcade E; Castagna L; Stölzel F; Sanz J; Tischer J; Ciceri F; Valcarcel D; Proia A; Hayden PJ; Beksac M; Yakoub-Agha I; Schönland S Transplant Cell Ther; 2021 Dec; 27(12):999.e1-999.e10. PubMed ID: 34543768 [TBL] [Abstract][Full Text] [Related]
29. Outcomes of Reduced-Intensity Conditioning Allogeneic Hematopoietic Cell Transplantation Performed in the Inpatient versus Outpatient Setting. Guru Murthy GS; Hari PN; Szabo A; Pasquini M; Narra R; Khan M; Abedin S; Chhabra S; Dhakal B; D'Souza A; Drobyski WR; Rizzo JD; Runaas L; Shah NN; Shaw B; Saber W; Fenske T; Hamadani M Biol Blood Marrow Transplant; 2019 Apr; 25(4):827-833. PubMed ID: 30572109 [TBL] [Abstract][Full Text] [Related]
30. The impact of intestinal microbiota in antithymocyte globulin-based myeloablative allogeneic hematopoietic cell transplantation. Gu Z; Xiong Q; Wang L; Wang L; Li F; Hou C; Dou L; Zhu B; Liu D Cancer; 2022 Apr; 128(7):1402-1410. PubMed ID: 35077579 [TBL] [Abstract][Full Text] [Related]
31. Valuing clinical strategies early in development: a cost analysis of allogeneic peripheral blood stem cell transplantation. Bennett C; Waters T; Stinson T; Almagor O; Pavletic Z; Tarantolo S; Bishop M Bone Marrow Transplant; 1999 Sep; 24(5):555-60. PubMed ID: 10482942 [TBL] [Abstract][Full Text] [Related]
32. Composite end point of graft-versus-host disease-free, relapse-free survival after allogeneic hematopoietic cell transplantation. Holtan SG; DeFor TE; Lazaryan A; Bejanyan N; Arora M; Brunstein CG; Blazar BR; MacMillan ML; Weisdorf DJ Blood; 2015 Feb; 125(8):1333-8. PubMed ID: 25593335 [TBL] [Abstract][Full Text] [Related]
33. Safety and efficacy of anti-programmed cell death-1 monoclonal antibodies before and after allogeneic hematopoietic cell transplantation for relapsed or refractory Hodgkin lymphoma: a multicenter retrospective study. Ito A; Kim SW; Matsuoka KI; Kawakita T; Tanaka T; Inamoto Y; Toubai T; Fujiwara SI; Fukaya M; Kondo T; Sugita J; Nara M; Katsuoka Y; Imai Y; Nakazawa H; Kawashima I; Sakai R; Ishii A; Onizuka M; Takemura T; Terakura S; Iida H; Nakamae M; Higuchi K; Tamura S; Yoshioka S; Togitani K; Kawano N; Suzuki R; Suzumiya J; Izutsu K; Teshima T; Fukuda T Int J Hematol; 2020 Nov; 112(5):674-689. PubMed ID: 32748216 [TBL] [Abstract][Full Text] [Related]
34. Post-Transplant Cyclophosphamide and Tacrolimus-Mycophenolate Mofetil Combination Prevents Graft-versus-Host Disease in Allogeneic Peripheral Blood Hematopoietic Cell Transplantation from HLA-Matched Donors. Carnevale-Schianca F; Caravelli D; Gallo S; Coha V; D'Ambrosio L; Vassallo E; Fizzotti M; Nesi F; Gioeni L; Berger M; Polo A; Gammaitoni L; Becco P; Giraudo L; Mangioni M; Sangiolo D; Grignani G; Rota-Scalabrini D; Sottile A; Fagioli F; Aglietta M Biol Blood Marrow Transplant; 2017 Mar; 23(3):459-466. PubMed ID: 28039079 [TBL] [Abstract][Full Text] [Related]
35. Long term survival among patients who are disease free at 1-year post allogeneic hematopoietic cell transplantation: a single center analysis of 389 consecutive patients. Solh MM; Bashey A; Solomon SR; Morris LE; Zhang X; Brown S; Holland HK Bone Marrow Transplant; 2018 May; 53(5):576-583. PubMed ID: 29335633 [TBL] [Abstract][Full Text] [Related]
37. [Second allogeneic hematopoietic stem cell transplantation with reduced-intensity conditioning and donor changes in relapsed hematological malignancies after the first allogeneic transplant]. Zhao YQ; Song YZ; Li ZH; Yang F; Xu T; Li FF; Yang DF; Wu T Zhonghua Xue Ye Xue Za Zhi; 2023 Jun; 44(6):465-471. PubMed ID: 37550201 [No Abstract] [Full Text] [Related]
38. Improved Long-Term Net Survival after Allogeneic Hematopoietic Cell Transplantation in Patients with Hematologic Malignancies over Two Decades. Ohbiki M; Ito Y; Inamoto Y; Miyamura K; Uchida N; Fukuda T; Fujiwara H; Nishida T; Hayashi M; Tanaka M; Kawakita T; Ikegame K; Katayama Y; Ara T; Ichinohe T; Kiyoi H; Matsuo K; Atsuta Y Transplant Cell Ther; 2023 Dec; 29(12):768.e1-768.e10. PubMed ID: 37739224 [TBL] [Abstract][Full Text] [Related]
39. Are we making progress in GVHD prophylaxis and treatment? Pavletic SZ; Fowler DH Hematology Am Soc Hematol Educ Program; 2012; 2012():251-64. PubMed ID: 23233589 [TBL] [Abstract][Full Text] [Related]
40. Cytotoxic Pathways in Allogeneic Hematopoietic Cell Transplantation. Du W; Cao X Front Immunol; 2018; 9():2979. PubMed ID: 30631325 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]